BIOMARCK PHARMACEUTICALS, LTD
DURHAM, NC · CIK 0001318185 · Biotech · Private
BIO-11006, a MARCKS-inhibitory peptide therapeutic for intraocular inflammation
- Grants
- $1.2M
- 2 awards
- Sector median: 1
- Raised
- $8.0M
- 3 Form D · Feb 2017
- 116 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 16
- 3 granted · 13 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201220132014201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $266,446 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Development of a Therapeutic Agent for COPD | $1,000,000 | |
| Private capital raised | Form D · SEC | $7,000,000 | |
| Private capital raised | Form D · SEC | $751,320 | |
| Federal grant | Department of Health and Human Services · Phase I · MARCKS: A novel therapeutic target in uveitis | $197,556 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2490 | 3+2 PHARMA, LLC | — | — |
| 2491 | CELL DATA SCIENCES, INC. | — | — |
| 2492 | Cerevel Therapeutics | — | — |
| 2493 | BIOMARCK PHARMACEUTICALS, LTD | — | $8.0M |
| 2494 | AMYGDALA NEUROSCIENCES, INC. | — | $7.0M |
| 2495 | Cirrus Therapeutics, Inc. | — | $6.7M |
| 2496 | Semnur Pharmaceuticals, Inc. | — | $6.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Rajin AhujaDirector
- Thorsten BeyerDirector
- Ashish BhatiaDirector
- Craig CollardDirector
- Brian DicksonExecutive Officer
- Ron DoggettDirector
- Michael EnrightExecutive Officer
- Allen GantDirector · Executive Officer
- Robin HenningExecutive Officer
- Robert KennelDirector
- Walker LongDirector
- Mohit MehrotraDirector
- Mark MuellerDirector · Executive Officer
- Laura NasirDirector
- Kennedy O'HerronDirector
- Indu ParikhDirector · Executive Officer
- Thomas RobergDirector
Patents
- Methods For Attenuating Release Of Inflammatory Mediators And Peptides Useful Thereinapplication
- Methods For Attenuating Release Of Inflammatory Mediators And Peptides Useful Thereinapplication
- Methods For Attenuating Release Of Inflammatory Mediators And Peptides Useful Thereinapplication
- Methods For Attenuating Release Of Inflammatory Mediators And Peptides Useful Thereinapplication
- Methods For Attenuating Release Of Inflammatory Mediators And Peptides Useful Thereingranted
- Mucin Hypersecretion Inhibitors And Methods Of Usegranted
- Mucin Hypersecretion Inhibitors And Methods Of Usegranted
- Peptides And Methods Of Use Thereof In Treating Uveitisapplication
- Peptides And Methods Of Use Thereof In Treating Skin Diseasesapplication
- Methods Of Modulating Mesenchymal Stem Cellsapplication
- Methods For Attenuating Release Of Inflammatory Mediators And Peptides Useful Thereinapplication
- Peptides And Methods Of Use Thereof In Treating Skin Diseasesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.